These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10595347)

  • 1. Progress in antisense technology: the end of the beginning.
    Crooke ST
    Methods Enzymol; 2000; 313():3-45. PubMed ID: 10595347
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.
    Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E
    Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of antisense oligonucleotides.
    Agrawal S; Temsamani J; Galbraith W; Tang J
    Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of antisense and triplex-forming oligonucleotides.
    François JC; Lacoste J; Lacroix L; Mergny JL
    Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350
    [No Abstract]   [Full Text] [Related]  

  • 5. Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides.
    Dheur S; Saison-Behmoaras TE
    Methods Enzymol; 2000; 313():56-73. PubMed ID: 10595349
    [No Abstract]   [Full Text] [Related]  

  • 6. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
    Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
    Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro transport and delivery of antisense oligonucleotides.
    Hughes J; Astriab A; Yoo H; Alahari S; Liang E; Sergueev D; Shaw BR; Juliano RL
    Methods Enzymol; 2000; 313():342-58. PubMed ID: 10595365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments.
    Stein CA
    Biochim Biophys Acta; 1999 Dec; 1489(1):45-52. PubMed ID: 10806996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense technology: commercial implications.
    Hawkins JW
    Antisense Res Dev; 1991; 1(3):283-4. PubMed ID: 1821649
    [No Abstract]   [Full Text] [Related]  

  • 10. Antisense oligonucleotides: preparation and in vivo application to rat brain.
    Tischmeyer W
    Methods Enzymol; 2000; 314():275-90. PubMed ID: 10565020
    [No Abstract]   [Full Text] [Related]  

  • 11. A cytosine analog that confers enhanced potency to antisense oligonucleotides.
    Flanagan WM; Wolf JJ; Olson P; Grant D; Lin KY; Wagner RW; Matteucci MD
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3513-8. PubMed ID: 10097067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development.
    Holmlund JT
    Ann N Y Acad Sci; 2003 Dec; 1002():244-51. PubMed ID: 14751839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
    Temsamani J; Roskey A; Chaix C; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crohn's trial shows the pros of antisense.
    Robertson D
    Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
    [No Abstract]   [Full Text] [Related]  

  • 15. 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) for effective antisense formation.
    Morita K; Yamate K; Kurakata S; Watanabe K; Imanishi T; Koizumi M
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1619-21. PubMed ID: 14565480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cellular internalization of fluoresceinated oligonucleotides.
    Benimetskaya L; Tonkinson J; Stein CA
    Methods Enzymol; 2000; 313():287-97. PubMed ID: 10595362
    [No Abstract]   [Full Text] [Related]  

  • 17. Basic principles of using antisense oligonucleotides in vivo.
    Phillips MI; Zhang YC
    Methods Enzymol; 2000; 313():46-56. PubMed ID: 10595348
    [No Abstract]   [Full Text] [Related]  

  • 18. Antisense oligonucleotides in lung cancer.
    Pujol JL; Jacot W
    Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antisense oligonucleotides--a new generation of potential drugs].
    Moser HE
    Praxis (Bern 1994); 1995 Sep; 84(38):1055-6. PubMed ID: 7481305
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic potential of antisense nucleic acid molecules.
    Opalinska JB; Gewirtz AM
    Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.